HOME >> BIOLOGY >> NEWS
Swine vaccine developed by veterinary college researcher receives USDA approval for commercial use

BLACKSBURG, June 22, 1999--A genetically altered vaccine developed by a researcher in the Virginia-Maryland Regional College of Veterinary Medicine has received the final green light from the United States Department of Agriculture (USDA) and is now being commercially marketed as an agent to prevent pneumonia in pigs.

The vaccine, marketed under the trade name "Actinobacillus Pleuropneumoniae Attenuate Live Culture" (APP-ALC) by Boehringer Engleheim /NOBL Laboratories, is the first avirulent live vaccine ever approved for preventing bacterial respiratory disease in animals, according to microbiologist Thomas Inzana, professor in the college's Department of Biomedical Sciences and Pathobiology. Swine pleuropneumoniae causes millions of dollars in production losses a year and is one of the most significant bacterial respiratory diseases in the swine industry, Inzana says.

"It can really wipe out a non-immune herd," he said, adding that an infection can destroy up to half of the herd and sicken most of the others. It's highly virulent characteristics pose a special threat for modern swine production centers where animals are highly concentrated.

The product development and licensing caps a several-year research effort which was made possible by the dramatic scientific advancements in the field of molecular biology over the past ten years.

Since the days of Pasteur, immunology researchers have known that the best immune response is elicited by natural exposure to the pathogenic organism itself, Inzana explains. Unfortunately, many vaccines evoke an inflammatory response and infection in the people and animals they are designed to protect. Working in the college's Center for Molecular Medicine and Infectious Disease, Inzana and colleagues sought to create a genetically altered live vaccine for swine pleuropneumonia, a major cause of production losses in the swine industry, which is caused by the bacterium Actinobacillus pleuropneumoniae.

I
'"/>

Contact: Dr. Thomas J. Inzana
Tinzana@vt.edu
540-231-4692
Virginia Tech
22-Jun-1999


Page: 1 2

Related biology news :

1. NADC Examines TB In Cattle and Swine
2. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
3. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
4. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. Protective gene may enhance vaccine responses
7. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
8. New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine
9. Growing new breed of vaccine-producing plants to fight human diseases worldwide
10. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
11. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... , ... October 23, 2019 , ... ... Christina Hughes , to its executive leadership team. , As a market ... solutions allow growth-stage biotech and pharma companies to reduce timelines and improve quality ...
(Date:10/26/2019)... ... October 25, 2019 , ... ... built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food ... advanced helium leak detection system, the SIMS Model 1915+ . The SIMS ...
(Date:10/22/2019)... ... ... Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group ... Sector,” with German biotech strategy consulting firm, Catenion. The seminar will take place from ... . , Speakers from Greenberg Traurig and Catenion will discuss best practices and practical ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... ... November 08, 2019 , ... ... intelligence (AI)-powered technology for use in pathology research, today announced the results ... samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). Strong ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. ... interface, the Fusion Bx 2.0 will give urologists across Europe the ability to ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing ... researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... to announce its Silver sponsorship and cold chain validation workshop at the Biomanufacturing ... Pines in San Diego, California. , The Biomanufacturing World Summit brings ...
Breaking Biology Technology:
Cached News: